Immunization with peptides derived from the idiotypic region of lupus-associated autoantibodies delays the development of lupus nephritis in the (SWR × NZB)F1 murine model

Journal of Autoimmunity

Volumn 29, Issue 1, 2007, Pages 30-37

  Stoll, Matthew L ^a   Price, Karen D ^a   Silvin, Christopher J ^a   Jiang, Feng ^a   Gavalchin, Jerrie ^a,b  

^a SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^b Department of Medicine ^*  (United States)

Author keywords

Idiopeptide; Immunization; Murine lupus; Tolerance

Indexed keywords

AUTOANTIBODY; DNA ANTIBODY; IDIOTYPIC ANTIBODY; IMMUNOGLOBULIN; MONOCLONAL ANTIBODY; NEPHRITOGENIC ANTIGEN; PEPTIDE A6.1[58-69]; PEPTIDE DERIVATIVE; PEPTIDE ID540; PEPTIDE ID540[62-73]; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; CROSS REACTION; FEMALE; IMMUNIZATION; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOLOGICAL TOLERANCE; LUPUS ERYTHEMATOSUS NEPHRITIS; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; ANIMALS; AUTOANTIBODIES; FEMALE; IMMUNIZATION; KIDNEY; LUPUS NEPHRITIS; MALE; MICE; MICE, INBRED NZB; MOLECULAR SEQUENCE DATA; PEPTIDES; PROTEINURIA;

EID: 34347351313     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2007.03.003     Document Type: Article

References (55)

1. Lawrence R.C., Helmick C.G., Arnett F.C., Deyo R.A., Felson D.T., Giannini E.H., et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 41 (1998) 778-799
2. Tomer Y., Buskila D., and Shoenfeld Y. Pathogenic significance and diagnostic value of lupus autoantibodies. Int Arch Allergy Immunol 100 (1993) 293-306
3. Linnik M.D., Hu J.Z., Heilbrunn K.R., Strand V., Hurley F.L., and Joh T. Relationship between anti-double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus. Arthritis Rheum 52 (2005) 1129-1137
4. Lefkowith J.B., and Gilkeson G.S. Nephritogenic autoantibodies in lupus: current concepts and continuing controversies. Arthritis Rheum 39 (1996) 894-903
5. Kubo C., Day N.K., and Good R.A. Influence of early or late dietary restriction on life span and immunological parameters in MRL/Mp-lpr/lpr mice. Proc Natl Acad Sci U S A 81 (1984) 5831-5835
6. Knupp C.J., Uner A.H., Korthas C., and Gavalchin J. Characterization of IdLNF1-specific T cell clones from the (NZB × SWR)F1 murine model for systemic lupus erythematosus. Clin Immunol Immunopathol 68 (1993) 273-282
7. Uner A.H., Knupp C.J., Tatum A.H., and Gavalchin J. Treatment with antibody reactive with the nephritogenic idiotype, IdLNF1, suppresses its production and leads to prolonged survival of (NZB × SWR)F1 mice. J Autoimmun 7 (1994) 27-44
8. Gilkeson G.S., Ruiz P., Pippen A.M., Alexander A.L., Lefkowith J.B., and Pisetsky D.S. Modulation of renal disease in autoimmune NZB/NZW mice by immunization with bacterial DNA. J Exp Med 183 (1996) 1389-1397
9. Mittleman B.B., Morse III H.C., Payne S.M., Shearer G.M., and Mozes E. Amelioration of experimental systemic lupus erythematosus (SLE) by retrovirus infection. J Clin Immunol 16 (1996) 230-236
10. Bagavant H., and Fu S.M. New insights from murine lupus: disassociation of autoimmunity and end organ damage and the role of T cells. Curr Opin Rheumatol 17 (2005) 523-528
11. Fricke H., Mendlovic S., Blank M., Shoenfeld Y., Ben-Bassat M., and Mozes E. Idiotype specific T-cell lines inducing experimental systemic lupus erythematosus in mice. Immunology 73 (1991) 421-427
12. Villarreal G.M., Drenkard C., Villa A.R., Slor H., Shafrir S., Bakimer R., et al. Prevalence of 13 autoantibodies and of the 16/6 and related pathogenic idiotypes in 465 patients with systemic lupus erythematosus and their relationship with disease activity. Lupus 6 (1997) 425-435
13. Gavalchin J., Nicklas J.A., Eastcott J.W., Madaio M.P., Stollar B.D., Schwartz R.S., et al. Lupus prone (SWR × NZB)F1 mice produce potentially nephritogenic autoantibodies inherited from the normal SWR parent. J Immunol 134 (1985) 885-894
14. Gavalchin J., and Datta S.K. The NZB × SWR model of lupus nephritis. II. Autoantibodies deposited in renal lesions show a distinctive and restricted idiotypic diversity. J Immunol 138 (1987) 138-148
15. Gavalchin J., Seder R.A., and Datta S.K. The NZB × SWR model of lupus nephritis. I. Cross-reactive idiotypes of monoclonal anti-DNA antibodies in relation to antigenic specificity, charge, and allotype. Identification of interconnected idiotype families inherited from the normal SWR and the autoimmune NZB parents. J Immunol 138 (1987) 128-137
16. Knupp C.J., Uner A.H., Tatum A.H., and Gavalchin J. The onset of nephritis in the (NZB × SWR)F1 murine model for systemic lupus erythematosus correlates with an increase in the ratio of CD4 to CD8 T lymphocytes specific for the nephritogenic idiotype (IdLNF1). Clin Immunol Immunopathol 65 (1992) 167-175
17. Price K., Knupp C.J., Tatum A.H., Jiang F., Stoll M., and Gavalchin J. Molecular identification of pathogenetic IdLNF + 1 autoantibody idiotypes derived from the NZBxSWR F1 model for systemic lupus erythematosus. J Autoimmun 19 (2002) 87-101
18. Tsao B.P., Ebling F.M., Roman C., Panosian-Sahakian N., Calame K., and Hahn B.H. Structural characteristics of the variable regions of immunoglobulin genes encoding a pathogenic autoantibody in murine lupus. J Clin Invest 85 (1990) 530-540
19. Ebling F.M., Tsao B.P., Singh R.R., Sercarz E., and Hahn B.H. A peptide derived from an autoantibody can stimulate T cells in the (NZB × NZW)F1 mouse model of systemic lupus erythematosus. Arthritis Rheum 36 (1993) 355-364
20. Singh R.R., Ebling F.M., Sercarz E.E., and Hahn B.H. Immune tolerance to autoantibody-derived peptides delays development of autoimmunity in murine lupus. J Clin Invest 96 (1995) 2990-2996
21. Singh R.R., Kumar V., Ebling F.M., Southwood S., Sette A., Sercarz E.E., et al. T cell determinants from autoantibodies to DNA can upregulate autoimmunity in murine systemic lupus erythematosus. J Exp Med 181 (1995) 2017-2027
22. Tillman D.M., Jou N.T., Hill R.J., and Marion T.N. Both IgM and IgG anti-DNA antibodies are the products of clonally selective B cell stimulation in (NZB × NZW)F1 mice. J Exp Med 176 (1992) 761-779
23. Shan H., Shlomchik M.J., Marshak-Rothstein A., Pisetsky D.S., Litwin S., and Weigert M.G. The mechanism of autoantibody production in an autoimmune MRL/lpr mouse. J Immunol 153 (1994) 5104-5120
24. Anker R., Zavala F., and Pollok B.A. VH and VL region structure of antibodies that recognize the (NANP)3 dodecapeptide sequence in the circumsporozoite protein of Plasmodium falciparum. Eur J Immunol 20 (1990) 2757-2761
25. Leaker B., Fairley K.F., Dowling J., and Kincaid-Smith P. Lupus nephritis: clinical and pathological correlation. Q J Med 62 (1987) 163-179
26. Elias D., and Cohen I.R. Peptide therapy for diabetes in NOD mice. Lancet 343 (1994) 704-706
27. Tian J., Atkinson M.A., Clare-Salzler M., Herschenfeld A., Forsthuber T., Lehmann P.V., et al. Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes. J Exp Med 183 (1996) 1561-1567
28. Shenoy M., Oshima M., Atassi M.Z., and Christadoss P. Suppression of experimental autoimmune myasthenia gravis by epitope-specific neonatal tolerance to synthetic region alpha 146-162 of acetylcholine receptor. Clin Immunol Immunopathol 66 (1993) 230-238
29. James J.A., and Harley J.B. A model of peptide-induced lupus autoimmune B cell epitope spreading is strain specific and is not H-2 restricted in mice. J Immunol 160 (1998) 502-508
30. Kaliyaperumal A., Michaels M.A., and Datta S.K. Antigen-specific therapy of murine lupus nephritis using nucleosomal peptides: tolerance spreading impairs pathogenic function of autoimmune T and B cells. J Immunol 162 (1999) 5775-5783
31. Wu H.Y., Ward F.J., and Staines N.A. Histone peptide-induced nasal tolerance: suppression of murine lupus. J Immunol 169 (2002) 1126-1134
32. Kang H.K., Michaels M.A., Berner B.R., and Datta S.K. Very low-dose tolerance with nucleosomal peptides controls lupus and induces potent regulatory T cell subsets. J Immunol 174 (2005) 3247-3255
33. Sakai K., Zamvil S.S., Mitchell D.J., Hodgkinson S., Rothbard J.B., and Steinman L. Prevention of experimental encephalomyelitis with peptides that block interaction of T cells with major histocompatibility complex proteins. Proc Natl Acad Sci U S A 86 (1989) 9470-9474
34. Katsiari C.G., and Tsokos G.C. Re-establishment of tolerance: the prospect of developing specific treatment for human lupus. Lupus 13 (2004) 485-488
35. Jouanne C., Avrameas S., and Payelle-Brogard B. A peptide derived from a polyreactive monoclonal anti-DNA natural antibody can modulate lupus development in (NZBxNZW)F1 mice. Immunology 96 (1999) 333-339
36. Mendlovic S., Brocke S., Shoenfeld Y., Ben-Bassat M., Meshorer A., Bakimer R., and Mozes E. Induction of a systemic lupus erythematosus-like disease in mice by a common human anti-DNA idiotype. Proc Natl Acad Sci U S A 85 (1988) 2260-2264
37. Waisman A., Ruiz P.J., Israeli E., Eilat E., Konen-Waisman S., Zinger H., et al. Modulation of murine systemic lupus erythematosus with peptides based on complementarity determining regions of a pathogenic anti-DNA monoclonal antibody. Proc Natl Acad Sci U S A 94 (1997) 4620-4625
38. Brosh N., Zinger H., and Mozes E. Treatment of induced murine SLE with a peptide based on the CDR3 of an anti-DNA antibody reverses the pattern of pathogenic cytokines. Autoimmunity 35 (2002) 211-219
39. Zinger H., Eilat E., Meshorer A., and Mozes E. Peptides based on the complementarity-determining regions of a pathogenic autoantibody mitigate lupus manifestations of (NZB × NZW)F1 mice via active suppression. Int Immunol 15 (2003) 205-214
40. Luger D., Dayan M., Zinger H., Liu J.P., and Mozes E. A peptide based on the complementarity determining region 1 of a human monoclonal autoantibody ameliorates spontaneous and induced lupus manifestations in correlation with cytokine immunomodulation. J Clin Immunol 24 (2004) 579-590
41. Rapoport M.J., Sharabi A., Aharoni D., Bloch O., Zinger H., Dayan M., et al. Amelioration of SLE-like manifestations in (NZBxNZW)F1 mice following treatment with a peptide based on the complementarity determining region 1 of an autoantibody is associated with a down-regulation of apoptosis and of the pro-apoptotic factor JNK kinase. Clin Immunol 117 (2005) 262-270
42. Singh R.R., and Hahn B.H. Reciprocal T-B determinant spreading develops spontaneously in murine lupus: implications for pathogenesis. Immunol Rev 164 (1998) 201-208
43. Ehrenstein M.R., and Hahn B. T cell-B cell interactions. Lupus 11 (2002) 790-792
44. Munthe L.A., Corthay A., Os A., Zangani M., and Bogen B. Systemic autoimmune disease caused by autoreactive B cells that receive chronic help from Ig V region-specific T cells. J Immunol 175 (2005) 2391-2400
45. Margulies D.H. Interactions of TCRs with MHC-peptide complexes: a quantitative basis for mechanistic models. Curr Opin Immunol 9 (1997) 390-395
46. Hahn B.H., Singh R.R., Wong W.K., Tsao B.P., Bulpitt K., and Ebling F.M. Treatment with a consensus peptide based on amino acid sequences in autoantibodies prevents T cell activation by autoantigens and delays disease onset in murine lupus. Arthritis Rheum 44 (2001) 432-441
47. Kaliyaperumal A., Mohan C., Wu W., and Datta S.K. Nucleosomal peptide epitopes for nephritis-inducing T helper cells of murine lupus. J Exp Med 183 (1996) 2459-2469
48. Sette A., Buus S., Appella E., Smith J.A., Chesnut R., Miles C., et al. Prediction of major histocompatibility complex binding regions of protein antigens by sequence pattern analysis. Proc Natl Acad Sci U S A 86 (1989) 3296-3300
49. de Graaf K.L., Weissert R., Kjellen P., Holmdahl R., and Olsson T. Allelic variations in rat MHC class II binding of myelin basic protein peptides correlate with encephalitogenicity. Int Immunol 11 (1999) 1981-1988
50. Winer S., Gunaratnam L., Astsatourov I., Cheung R.K., Kubiak V., Karges W., et al. Peptide dose, MHC affinity, and target self-antigen expression are critical for effective immunotherapy of nonobese diabetic mouse prediabetes. J Immunol 165 (2000) 4086-4094
51. James J.A., Neas B.R., Moser K.L., Hall T., Bruner G.R., Sestak A.L., et al. Systemic lupus erythematosus in adults is associated with previous Epstein-Barr virus exposure. Arthritis Rheum 44 (2001) 1122-1126
52. Poole B.D., Scofield R.H., Harley J.B., and James J.A. Epstein-Barr virus and molecular mimicry in systemic lupus erythematosus. Autoimmunity 39 (2006) 63-70
53. McClain M.T., Lutz C.S., Kaufman K.M., Faig O.Z., Gross T.F., and James J.A. Structural availability influences the capacity of autoantigenic epitopes to induce a widespread lupus-like autoimmune response. Proc Natl Acad Sci U S A 101 (2004) 3551-3556
54. Hahn B.H., Singh R.P., La Cava A., and Ebling F.M. Tolerogenic treatment of lupus mice with consensus peptide induces Foxp3-expressing, apoptosis-resistant, TGFbeta-secreting CD8+T cell suppressors. J Immunol 175 (2005) 7728-7737
55. Sthoeger Z.M., Dayan M., Tcherniack A., Green L., Toledo S., Segal R., et al. Modulation of autoreactive responses of peripheral blood lymphocytes of patients with systemic lupus erythematosus by peptides based on human and murine anti-DNA autoantibodies. Clin Exp Immunol 131 (2003) 385-392